The company posted its results for the third quarter of FY26 late on Wednesday evening, with its revenue dipping 3% year-on-year to ₹2,140 crore, and slipping to a loss of ₹136 crore from a net profit of ₹4 crore in Q3FY25. Its ebitda margin shrank from 16% in Q3FY25 to 11% this fiscal.
Piramal Pharma points to early recovery signs after seeing red in Q3
